Advertisement

Search Results

Advertisement



Your search for all items matches 26046 pages

Showing 1 - 50


hepatobiliary cancer
immunotherapy

Neoadjuvant Cabozantinib/Nivolumab May Make Resection Possible for Some Patients With Liver Cancer

A combination of the kinase inhibitor cabozantinib and the immunotherapy nivolumab may make curative surgery possible for some patients with liver cancer who would generally not be considered candidates for surgery, according to research published by Ho et al in Nature Cancer. Rates of Resection...

covid-19

Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care Workers

In an Israeli single-institution prospective cohort study reported in The New England Journal of Medicine, Bergwerk et al identified breakthrough COVID-19 infections among 39 of 1,497 health-care workers fully vaccinated with the BNT162b2 (Pfizer-BioNTech) vaccine. As stated by the investigators:...

lymphoma

Impact of Nurse Navigation Program on Outcomes in Minority Patients With Aggressive Lymphoma

In a single-institution study reported in the journal Cancer, Hu et al found that use of a dedicated nurse navigation program contributed to redressing the recognized inequities in care and outcomes between minority patients and White patients with aggressive large B-cell lymphoma (LBCL).  As...

myelodysplastic syndromes

Continuous Azacitidine vs Reduced-Intensity Conditioning HSCT in Older Patients With Advanced Myelodysplastic Syndrome

In the German phase II VidazaAllo study reported in the Journal of Clinical Oncology, Kröger et al found that switching from azacitidine to reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation (HSCT) contingent upon donor availability was associated with better outcomes ...

Expert Point of View: Giuseppe Curigliano, MD, PhD

Invited discussant Giuseppe Curigliano, MD, PhD, Associate Professor of Medical Oncology at the University of Milan, Italy, and Head of the Division of Early Drug Development at the European Institute of Oncology, said the “clear” findings of KEYNOTE-5221 are “practice-changing.” However, the...

cns cancers

Carboplatin Intensification for the Treatment of Pediatric High-Risk Medulloblastoma

In a Children’s Oncology Group (COG) phase III trial reported in JAMA Oncology, Leary et al found that the addition of carboplatin to radiotherapy in pediatric patients with newly diagnosed high-risk medulloblastoma improved event-free survival in the group 3 molecular subgroup but not in others....

breast cancer

KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer

The latest analysis of the pivotal phase III KEYNOTE-522 trial demonstrated significant improvements in clinical outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone as a neoadjuvant/adjuvant treatment of triple-negative breast cancer.1 This is the first large, randomized, phase III...

Defining Cure in Multiple Myeloma

Recently, The ASCO Post published an article titled "Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar, MD." On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to “cure” patients, in light of the fact that multiple myeloma has been...

multiple myeloma
immunotherapy

Surbhi Sidana, MD, on CAR T-Cell Therapy and Bispecific Antibodies Targeting Myeloma

The session’s invited discussant Surbhi Sidana, MD, Assistant Professor of Medicine, Stanford University, said CAR T-cell therapy and bispecific antibodies targeting myeloma are emerging as potentially effective options for patients with highly refractory disease. For this population of triple...

multiple myeloma
immunotherapy

Bispecific Antibodies Advance in Relapsed or Refractory Multiple Myeloma

For the challenging population of patients with multiple myeloma who have become refractory to essentially all current treatments, new approaches are much needed. Early clinical trials data suggest bispecific antibodies may help meet this need, as suggested by studies presented at the 2021 ASCO...

covid-19

Study Shows Cancer Trials Adapted Rapidly During the COVID-19 Pandemic

Cancer clinical trial research rapidly adapted to the circumstances of enrolling and treating patients in clinical trials during the COVID-19 pandemic, according to findings from a study of enrollment during 2020 and early 2021 published by Joseph M. Unger, PhD, and colleagues in JAMA Network ...

solid tumors

Meta-analysis Identifies Genetic Markers for Inherited Testicular Cancer

A meta-analysis of nearly 200,000 men revealed 22 new genetic locations that could be susceptible to inherited testicular germ cell tumors—a 40% increase in the number of regions known to be associated with the cancer. The new findings, published by Pluta et al in Nature Communications, could help...

breast cancer
covid-19

Incidence of Axillary Adenopathy in Screening or Diagnostic Mammography After COVID-19 Vaccination

In a single-center retrospective study reported in a research letter in JAMA Oncology, Robinson et al found a vaccine-related axillary adenopathy incidence rate of 3% among women undergoing screening or diagnostic mammography within 90 days of receipt of at least one dose of a COVID-19 vaccine....

survivorship
issues in oncology

Frailty and Neurocognitive Decline Among Young Adult Childhood Cancer Survivors

In a prospective study from the St. Jude Lifetime Cohort reported in the Journal of Clinical Oncology, Williams et al found that prefrailty and frailty among young adult childhood cancer survivors were associated with neurocognitive decline vs nonfrail counterparts, mirroring the association...

issues in oncology

Association of Baseline Fatigue With Survival and Adverse Events in Patients With Advanced Cancer

In an analysis of four SWOG clinical trials of patients with advanced cancer reported in JCO Oncology Practice, Mo et al found that clinically significant fatigue at baseline was associated with poorer survival and increased risk of severe adverse events. Study Details The analysis included data...

gastrointestinal cancer
gastroesophageal cancer

Perioperative or Postoperative Oxaliplatin/S-1 vs Postoperative Oxaliplatin/Capecitabine for Locally Advanced Gastric Cancer

In the Chinese phase III RESOLVE trial reported in The Lancet Oncology, Zhang et al found that perioperative S-1/oxaliplatin was superior to—and adjuvant S-1/oxaliplatin was noninferior to—adjuvant capecitabine/oxaliplatin in terms of disease-free survival in patients undergoing D2 gastrectomy for...

issues in oncology

Study Examines Prevalence of Cancer Misinformation and Harmful Information on Social Media

Research shows that the majority of Americans—81%—are health-care information seekers, and that more than three-quarters of Americans get that information online. Unfortunately, much of that online information is inaccurate and could cause harm, according to a review of the most popular articles on ...

breast cancer
geriatric oncology
genomics/genetics

Risk of Breast Cancer in Women Older Than Age 65 With Germline Pathogenic Variants in Predisposition Genes

In a study reported in the Journal of Clinical Oncology, Boddicker et al found that women older than age 65 in the general population who carry germline pathogenic variants in established high-risk breast cancer predisposition genes remain at significant risk of late-onset breast cancer and should...

Expert Point of View: Lisa Carey, MD

NEOTALA’s invited discussant, Lisa Carey, MD, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research and Deputy Director of Clinical Sciences at the University of North Carolina-Chapel Hill, saw the findings as part of a bigger trend toward reducing the use of...

breast cancer

Single-Agent Talazoparib Shows Activity in the Neoadjuvant Treatment of Triple-Negative Breast Cancer

For the neoadjuvant treatment of triple-negative breast cancer, the oral poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib yielded promising pathologic complete response rates in the phase II single-arm NEOTALA trial presented at the 2021 ASCO Annual Meeting.1 Preoperative chemotherapy is...

sarcoma

ASTRO Issues New Clinical Guideline on Radiation Therapy for Adult Patients With Soft-Tissue Sarcoma

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) published by Kilian E. Salerno, MD, and colleagues in Practical Radiation Oncology provides guidance on the use of radiation therapy to treat adult patients with soft-tissue sarcomas. Recommendations outline optimal...

breast cancer

Study Explores Rates of Reconstruction for Women With Inflammatory Breast Cancer Undergoing Mastectomy

The percentage of patients with inflammatory breast cancer who select reconstructive surgery after mastectomy—whether immediate or delayed—remains low in spite of improvements in treatment and long-term survival, but the numbers are increasing, according to recent research published by Karadsheh et ...

multiple myeloma

FDA Alert: Clinical Trial Results Show an Increased Risk of Death Associated With Melphalan Flufenamide

The U.S. Food and Drug Administration (FDA) is alerting patients and health-care professionals that a clinical trial (OCEAN, Study OP-103; ClinicalTrials.gov identifier: NCT03151811) evaluating melphalan flufenamide with dexamethasone to treat patients with multiple myeloma showed an increased risk ...

issues in oncology
global cancer care

How Climate Change Is Impacting Cancer Care and What Can Be Done to Reduce Oncology’s Footprint on the Environment

Worldwide, the global average surface temperature has risen at a similar rate of 0.17°F per decade since 1901, with the warmest year on record occurring in 2016 and the second warmest occurring in 2020. However, according to NOAA, since the late 1970s, the United States has warmed faster than the...

solid tumors
hematologic malignancies

Complication Rates Among Central Venous Access Devices Compared

In the CAVA trial reported in The Lancet, Moss et al found that among central venous access devices used for the delivery of systemic anticancer therapy, totally implanted ports (PORTs) were associated with significantly reduced rates of complications compared with Hickman-type tunneled catheters...

pancreatic cancer

Comparison of First-Line Chemotherapy Strategies in Metastatic Pancreatic Cancer

In a French phase II trial (PANOPTIMOX-PRODIGE) reported in the Journal of Clinical Oncology, Dahan et al found that 4 months of FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) followed by leucovorin/fluorouracil maintenance was associated with favorable outcomes vs 6 months of...

palliative care
pain management

Trends in Opioid Prescriptions Among Patients With Cancer Near the End of Life

In a study reported in the Journal of Clinical Oncology, Enzinger et al found that the prescription of opioids for cancer pain dropped markedly in the recent past among patients with poor-prognosis disease near the end of life, with the frequency of pain-related emergency department visits...

leukemia
genomics/genetics

Can Treatment With Thiopurines Induce Mutations That May Lead to Pediatric Leukemia Relapse?

Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers. Now, a research team has shown how thiopurines may lead to mutations that set patients up for disease relapse. These findings were published by Yang et al in Nature Cancer. The research...

lymphoma
global cancer care

Study Explores Cost-Effectiveness of CHOP Therapy for Patients With DLBCL in Sub-Saharan Africa

In a clinical trial conducted in Malawi, researchers found that combination chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) provided curative benefit compared to current standard-of care therapy in people diagnosed with diffuse large B-cell lymphoma (DLBCL)—and...

issues in oncology

Survival Trends for Adolescents and Young Adults With Cancer: 40-Year Analysis

Survival rates for adolescents and young adults diagnosed with cancer vary considerably depending on the type of malignancy. A new study published by Riedel Lewis et al in the journal Cancer indicated that survival for multiple cancer types in such patients has improved in recent years, but some...

breast cancer

Expert Point of View: Evandro de Azambuja, MD, PhD

“KAITLIN didnot meet its primary endpoint, either in the intent-to-treat or node-positive population,1 but in context with the APHINITY trial [1 year of adjuvant pertuzumab/trastuzumab plus chemotherapy],2 whose outcomes were similar at 3 years, you can appreciate that both arms did extremely...

breast cancer

KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy for HER2-Positive Early Breast Cancer

In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) did not result in a significant improvement in invasive disease–free survival in the node-positive or intent-to-treat population of women with high-risk, HER2-positive early breast...

skin cancer
immunotherapy

Pembrolizumab Shows Durable Antitumor Activity in Both Locally Advanced and Recurrent/Metastatic Squamous Cell Carcinomas

The results of the second interim analysis of the KEYNOTE-629 study of pembrolizumab in cutaneous squamous cell carcinoma confirmed durable antitumor activity in both the locally advanced and the recurrent/metastatic settings. Adverse events with pembrolizumab were generally consistent with its...

head and neck cancer
palliative care

Weekly Outpatient Palliative Care Interventions Among Patients With Head and Neck Cancer

Over 90% of patients with head and neck cancer receiving curative-intent chemoradiation therapy found weekly palliative care visits to be a valuable addition to their treatment, a recent study published by Bauman et al in the Journal of Palliative Medicine found. Although palliative care is known...

geriatric oncology

Cancer vs Non–Cancer-Related Deaths Among Older Patients Selected for Surgical Treatment

In a Canadian population-based cohort study reported in JAMA Surgery, Chesney et al found that the 5-year rate of cancer-related deaths exceeded that of non–cancer-related deaths among patients aged 70 or older undergoing surgery for cancer.    Study Details The study used data from ICES (formerly...

prostate cancer
covid-19

Prostate Cancer Surgery Rates in Black vs White Men With Nonmetastatic Disease During the COVID-19 Pandemic

In a retrospective cohort study reported in JAMA Oncology, Bernstein et al found that prostatectomy rates during the initial wave of the COVID-19 pandemic were dramatically lower among Black men vs White men with previously untreated nonmetastatic prostate cancer. Study Details The study involved...

issues in oncology
global cancer care

Global Estimates of New Cancers Attributable to Alcohol Use in 2020

In a population-based study reported in The Lancet Oncology, Rumgay et al provided estimates of the global incidence of new cancers attributable to alcohol consumption, including the estimate that 4.1% of all new cases in 2020 were related to alcohol use. Study Details   In the study, population...

breast cancer
immunotherapy

FDA Approves Pembrolizumab in Combination for High-Risk, Early-Stage Triple-Negative Breast Cancer

On July 26, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. The FDA also...

breast cancer

HR-Positive/HER2-Positive Metastatic Breast Cancer

In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss the current treatment landscape for hormone receptor (HR)-positive, HER-positive metastatic breast cancer. Dr. Hurvitz presents the case of a 34-year-old woman with de novo metastatic estrogen...

breast cancer

ER-Positive/HER2-Positive Breast Cancer and Residual Disease

In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney turn their discussion to treatment options for HER2-positive breast cancer. Dr. Hurvitz presents a case of a 62-year-old woman diagnosed with high-grade cT1N1 estrogen receptor (ER)-positive/progesterone...

breast cancer

HR-Positive/HER2-Negative Early Breast Cancer

In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss the management of hormone receptor (HR)-positive, HER2-negative early breast cancer. The faculty present the case of a 54-year-old perimenopausal Black woman who has been diagnosed with high-grade T3N1 left...

breast cancer

Newly Diagnosed HER2-Negative Metastatic Breast Cancer

In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss current treatment options for newly diagnosed HER2-negative metastatic breast cancer. Dr. Hurvitz presents the case of a 49-year-old perimenopausal Latina woman with intermediate-grade T2N1 left breast cancer...

ASCO Honors John V. Cox, DO, MBA, FACP, FASCO, With 2021 Joseph V. Simone Award

ASCO will recognize John V. Cox, DO, MBA, FACP, FASCO, a medical oncologist and professor at the University of Texas Southwestern, with the Joseph V. Simone Award and Lecture for Excellence in Quality and Safety in the Care of Patients With Cancer. Dr. Cox will be presented with the award at the...

covid-19

ASCO/Friends of Cancer Research Joint Position Statement Encourages Enrollment of Patients With Cancer in COVID-19 Vaccine Studies

Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, ASCO and Friends of Cancer Research (Friends) asserted in a recently released joint position statement. To date, clinical...

ASCO Calls for Increased Funding for Cancer Research in Fiscal Year 2022

ASCO is calling on Congress to continue its bipartisan support of federally funded research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) baseline budgets are critical in advancing our nation’s work toward...

gynecologic cancers

ASCO Publishes Resource-Stratified Guideline on Assessment and Treatment of Ovarian Cancer

Ovarian cancer carries a heavy morbidity and mortality burden, particularly in settings and regions of the globe that feature significant limitations in health-care resources. Given that ovarian cancer is more lethal than breast cancer, clinicians in resource-limited areas require guidance on the...

immunotherapy
skin cancer

Benefits of Adjuvant Pembrolizumab in Melanoma Reinforced by EORTC 1325/KEYNOTE-054 Updates

Adjuvant anti–PD-1 antibody therapy is widely used for stage III melanoma, given the approvals of pembrolizumab and nivolumab. These approvals were based on significantly improved relapse-free survival in the CheckMate 238 trial of nivolumab compared with ipilimumab and the EORTC 1325/KEYNOTE-054...

skin cancer
immunotherapy

Adjuvant Pembrolizumab Improves Distant Metastasis–Free Survival in Resected High-Risk Stage III Melanoma

As reported in The Lancet Oncology by Alexander M.M. Eggermont, MD, of Princess Máxima Center, Utrecht, the Netherlands, and colleagues, the pivotal phase III EORTC 1325/KEYNOTE-054 trial has shown significant improvement in the secondary endpoint of distant metastasis–free survival, as well as...

lung cancer

Lorlatinib for Metastatic ALK-Positive NSCLC

On March 3, 2021, lorlatinib was granted regular approval for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with ALK-positive tumors as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA simultaneously approved the Ventana ALK (D5F3) CDx Assay ...

solid tumors
gastroesophageal cancer

Pembrolizumab Combined With Chemotherapy for Advanced Esophageal or Gastroesophageal Junction Carcinoma

On March 22, 2021, pembrolizumab was approved for use in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal junction (tumors with epicenter 1 to 5 cm above the gastroesophageal junction) carcinoma who...

Advertisement

Advertisement



Advertisement